Cargando…

Circulating tumor cells: silent predictors of metastasis

Circulating tumor cells (CTCs) were added to the arsenal of clinical testing in 2004 for three cancer types: metastatic breast, prostate, and colorectal cancer. CTCs were found to be an independent prognostic indicator of survival for these three diseases. Multiple enrichment/isolation strategies ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, LanLan, Dicker, David T., Matthew, Elizabeth, El-Deiry, Wafik S., Alpaugh, R. Katherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	F1000Research 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558099/ https://www.ncbi.nlm.nih.gov/pubmed/28868131 http://dx.doi.org/10.12688/f1000research.11313.1

Ejemplares similares

Detection of circulating tumor cells in the cerebrospinal fluid of a patient with a solitary metastasis from breast cancer: A case report
por: PATEL, AKSHAL S., et al.
Publicado: (2014)

Apoptotic circulating tumor cells (CTCs) in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCs
por: Allen, Joshua E., et al.
Publicado: (2013)

A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells
por: Matthew, Elizabeth M., et al.
Publicado: (2015)

Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90
por: Zhao, Shuai, et al.
Publicado: (2021)

Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases
por: Patel, Akshal S., et al.
Publicado: (2011)

A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53
por: Hernandez Borrero, Liz, et al.
Publicado: (2021)

Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells
por: Zhang, Shengliang, et al.
Publicado: (2022)

CTGF-mediated autophagy-senescence transition in tumor stroma promotes anabolic tumor growth and metastasis
por: Prabhu, Varun V., et al.
Publicado: (2012)

Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivo
por: Ray, Jocelyn E., et al.
Publicado: (2021)

AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing
por: Sahin, Ilyas, et al.
Publicado: (2020)

Correction: AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing
por: Sahin, Ilyas, et al.
Publicado: (2020)

A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs
por: Huntington, Kelsey E., et al.
Publicado: (2021)

TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic
por: Ralff, Marie D., et al.
Publicado: (2020)

Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms
por: Wagner, Jessica, et al.
Publicado: (2018)

ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer
por: Ferrarini, Isacco, et al.
Publicado: (2021)

P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9
por: Tian, Xiaobing, et al.
Publicado: (2021)

Integrating Molecular Biomarker Inputs Into Development and Use of Clinical Cancer Therapeutics
por: Louie, Anna D., et al.
Publicado: (2021)

Absence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies
por: Liguori, Nicholas R., et al.
Publicado: (2021)

Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis
por: Abdulghani, Junaid, et al.
Publicado: (2013)

First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent
por: Allen, Joshua E., et al.
Publicado: (2015)

Investing in biomedical research is important
por: El-Deiry, Wafik S
Publicado: (2013)

Welcoming Paul Dent as Assistant Editor-in-Chief of Cancer Biology & Therapy
por: El-Deiry, Wafik S
Publicado: (2013)

Are we losing the war on cancer?
por: El-Deiry, Wafik S
Publicado: (2013)

Targeting Mutated p53: Naivete and Enthusiasm to Attempt the Impossible
por: El-Deiry, Wafik S.
Publicado: (2023)

Correction: First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent
por: Allen, Joshua E., et al.
Publicado: (2016)

EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG
por: Zhang, Yiqun, et al.
Publicado: (2021)

Calcein-effluxing human colon cancer cells are enriched for self-renewal capacity and depend on β-catenin
por: Allen, Joshua E., et al.
Publicado: (2013)

Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway
por: Allen, Joshua E, et al.
Publicado: (2015)

The tuberous sclerosis complex gets fatter
por: Gokare, Prashanth, et al.
Publicado: (2017)

Challenges in Diversity, Equity, and Inclusion in Research and Clinical Oncology
por: El-Deiry, Wafik S., et al.
Publicado: (2021)

Identification of Smurf2 as a HIF-1α degrading E3 ubiquitin ligase
por: Zhao, Shuai, et al.
Publicado: (2021)

Differential p53-Mediated Cellular Responses to DNA-Damaging Therapeutic Agents
por: Carlsen, Lindsey, et al.
Publicado: (2021)

Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translation
por: Carlsen, Lindsey, et al.
Publicado: (2022)

Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab
por: Sahin, Ilyas, et al.
Publicado: (2021)

Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells
por: Carlsen, Lindsey, et al.
Publicado: (2021)

The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer
por: Allen, Joshua E., et al.
Publicado: (2013)

Correction: The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer
por: Allen, Joshua E., et al.
Publicado: (2013)

Targeting the Integrated Stress Response in Cancer Therapy
por: Tian, Xiaobing, et al.
Publicado: (2021)

Evaluating the probability of silent circulation of polio in small populations using the silent circulation statistic
por: Vallejo, Celeste, et al.
Publicado: (2019)

Regulation of the human TRAIL gene
por: Allen, Joshua E., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_4rhffmqrt08co1jda3jcvl7hvg